266 related articles for article (PubMed ID: 33253311)
21. Is use of a long-term proton pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in Taiwan? A neglected clinical drug-drug interaction.
Wu YT; Lu YT; Chu CY; Chao HJ; Kuo LN; Cheng KJ; Chen HY
Fam Pract; 2023 Sep; ():. PubMed ID: 37756627
[TBL] [Abstract][Full Text] [Related]
22. The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013.
Park SK; Baek YH; Pratt N; Kalisch Ellett L; Shin JY
Drug Saf; 2018 Jun; 41(6):615-624. PubMed ID: 29397553
[TBL] [Abstract][Full Text] [Related]
23. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
24. No association between acid suppressant use and risk of dementia: an updated meta-analysis.
Wang H; Tian L; Yan X
Eur J Clin Pharmacol; 2022 Mar; 78(3):375-382. PubMed ID: 34811582
[TBL] [Abstract][Full Text] [Related]
25. Effect of Gastric Acid Suppressants on Response to a Physical Activity Intervention and Major Mobility Disability in Older Adults: Results from the Lifestyle Interventions for Elders (LIFE) Study.
Squires PJ; Pahor M; Manini TM; Brown JD
Pharmacotherapy; 2019 Aug; 39(8):816-826. PubMed ID: 31230397
[TBL] [Abstract][Full Text] [Related]
26. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
27. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
[TBL] [Abstract][Full Text] [Related]
28. Proton pump inhibitor use and the risk for Parkinson's disease: A nationwide population-based study in Taiwan.
Chen HL; Lei WY; Wang JH; Bair MJ; Chen CL
Medicine (Baltimore); 2023 May; 102(19):e33711. PubMed ID: 37171333
[TBL] [Abstract][Full Text] [Related]
29. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
30. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
[TBL] [Abstract][Full Text] [Related]
31. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C.
Kao WY; Su CW; Chia-Hui Tan E; Lee PC; Chen PH; Tang JH; Huang YH; Huo TI; Chang CC; Hou MC; Lin HC; Wu JC
Hepatology; 2019 Mar; 69(3):1151-1164. PubMed ID: 30175498
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.
Brown JP; Tazare JR; Williamson E; Mansfield KE; Evans SJ; Tomlinson LA; Bhaskaran K; Smeeth L; Wing K; Douglas IJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3150-3161. PubMed ID: 33393677
[TBL] [Abstract][Full Text] [Related]
33. Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK Biobank.
Fan X; Liu Z; Miyata T; Dasarathy S; Rotroff DM; Wu X; Poulsen KL; Nagy LE
Gastroenterology; 2021 Jan; 160(1):455-458.e5. PubMed ID: 32980342
[No Abstract] [Full Text] [Related]
34. Risk of systemic autoimmune diseases in gastric disease patients with proton pump inhibitor use: a nationwide cohort study in Taiwan.
Chen HY; Lin JJ; Yang B; Lin MC
Clin Rheumatol; 2020 Sep; 39(9):2773-2780. PubMed ID: 32152918
[TBL] [Abstract][Full Text] [Related]
35. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
37. Signal and Noise: Proton Pump Inhibitors and the Risk of Dementia?
Friesen KJ; Falk J; Chateau D; Kuo IF; Bugden S
Clin Pharmacol Ther; 2023 Jan; 113(1):152-159. PubMed ID: 36260313
[TBL] [Abstract][Full Text] [Related]
38. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.
Song TJ; Kim J
PLoS One; 2019; 14(5):e0216750. PubMed ID: 31067267
[TBL] [Abstract][Full Text] [Related]
39. Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK.
Cooksey R; Kennedy J; Dennis MS; Escott-Price V; Lyons RA; Seaborne M; Brophy S
PLoS One; 2020; 15(9):e0237676. PubMed ID: 32946449
[TBL] [Abstract][Full Text] [Related]
40. Exposure to acid-suppressing drugs during pregnancy and the risk of asthma in childhood: an observational cohort study.
Cea Soriano L; Hernández-Díaz S; Johansson S; Nagy P; García-Rodríguez LA
Aliment Pharmacol Ther; 2016 Feb; 43(3):427-37. PubMed ID: 26612701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
